Upcoming Events & Webinars
Join our events and webinars to meet experts, build collaborations and be the first to see new product releases.
Upcoming Webinars
-
2023-06-19T14:00:00Z
Why is rare variant detection and discovery from cfDNA so challenging?
Studies have shown that both cfDNA and ctDNA correlate with disease progression and reoccurrence and assist in therapy guidance. But cfDNA is highly fragmented, unstable in biofluids and at low concentrations in non-advanced, non-metastatic cancers. Meanwhile, ctDNA represents just 1–2% of total cfDNA. Add in sequencing reaction errors, enrichment biases and false positives, and you will need a lower limit of detection (LOD) of about 0.1% variant allele frequency (VAF) to find those valuable insights. To be confident in your rare variant identification, cfDNA requires highly sensitive and specific techniques.Join us for a webinar discussing the newest technology for reliable detection of ultra-rare variants at a 0.1% VAF from cfDNA and go from sample to sequencing-ready library in just 8 hours. We will discuss the following:
- The biggest challenges in liquid biopsy variant detection
- Our new QIAseq chemistry and workflow
- Simplified data analysis with our integrated bioinformatics pipeline
Explore how our new QIAseq Targeted cfDNA Ultra Panels can help you unlock the potential in your liquid biopsy samples.
Krishna Amin, Senior Global Product Manager-Targeted Genomics
-
2023-06-20T15:00:00Z
Adeno-associated virus (AAV) has emerged as the primary vector for in vivo gene therapy applications. AAV samples are measured and dosed based on DNA concentration, traditionally assessed through conventional quantitative PCR (qPCR). However, digital PCR methods, which allow for absolute quantification of target sequences and eliminate the need for a standard curve, are replacing qPCR methods due to their improved precision. An accurate AAV titration method is crucial throughout the entire drug development process, including preclinical studies, process development, and clinical dosing.
This webinar will cover the following topics:- Highlights of method development for establishing well-controlled AAV titration methods
- Comparison of multiple digital PCR platforms for AAV titration
- Strategies for transitioning from legacy qPCR methods to enhanced digital PCR platforms
Stuart Nelson, Technical Lead of Analytical Control Strategy
-
2023-06-21T09:00:00Z
Adeno-associated virus (AAV) has emerged as the primary vector for in vivo gene therapy applications. AAV samples are measured and dosed based on DNA concentration, traditionally assessed through conventional quantitative PCR (qPCR). However, digital PCR methods, which allow for absolute quantification of target sequences and eliminate the need for a standard curve, are replacing qPCR methods due to their improved precision. An accurate AAV titration method is crucial throughout the entire drug development process, including preclinical studies, process development, and clinical dosing.
This webinar will cover the following topics:- Highlights of method development for establishing well-controlled AAV titration methods
- Comparison of multiple digital PCR platforms for AAV titration
- Strategies for transitioning from legacy qPCR methods to enhanced digital PCR platforms
Stuart Nelson, Technical Lead of Analytical Control Strategy